Advertisement

Index by Author

March 1998; 47 (3)
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z

A

  1. Abdel-Halim, S M

    • Mutations in the promoter of adenylyl cyclase (AC)-III gene, overexpression of AC-III mRNA, and enhanced cAMP generation in islets from the spontaneously diabetic GK rat model of type 2 diabetes. Diabetes March 1998 47:498-504; doi:10.2337/diabetes.47.3.498

  2. Aguilar-Bryan, L

    • Identification and functional analysis of sulfonylurea receptor 1 variants in Japanese patients with NIDDM. Diabetes March 1998 47:476-481; doi:10.2337/diabetes.47.3.476

  3. Akbari, C M

    • Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes March 1998 47:457-463; doi:10.2337/diabetes.47.3.457

  4. Allen, T J

    • Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes March 1998 47:414-422; doi:10.2337/diabetes.47.3.414

  5. Amatruda, J M

    • 13C/31P NMR studies on the mechanism of insulin resistance in obesity. Diabetes March 1998 47:381-386; doi:10.2337/diabetes.47.3.381

  6. Ardehali, H

    • Insulin-induced hexokinase II expression is reduced in obesity and NIDDM. Diabetes March 1998 47:387-394; doi:10.2337/diabetes.47.3.387

  7. Aubert, R

    • Novel polymorphisms in the 5' region of the LEP gene: association with leptin levels and response to low-calorie diet in human obesity. Diabetes March 1998 47:487-489; doi:10.2337/diabetes.47.3.487

  8. Auwerx, J

    • Human peroxisome proliferator-activated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. Diabetes March 1998 47:490-492; doi:10.2337/diabetes.47.3.490

  9. Aviv, A

    • Shortened telomere length in white blood cells of patients with IDDM. Diabetes March 1998 47:482-486; doi:10.2337/diabetes.47.3.482

  10. Aviv, H

    • Shortened telomere length in white blood cells of patients with IDDM. Diabetes March 1998 47:482-486; doi:10.2337/diabetes.47.3.482

B

  1. Bakhiet, M

    • Mutations in the promoter of adenylyl cyclase (AC)-III gene, overexpression of AC-III mRNA, and enhanced cAMP generation in islets from the spontaneously diabetic GK rat model of type 2 diabetes. Diabetes March 1998 47:498-504; doi:10.2337/diabetes.47.3.498

  2. Benigni, A

    • Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes March 1998 47:450-456; doi:10.2337/diabetes.47.3.450

  3. Bertani, T

    • Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes March 1998 47:450-456; doi:10.2337/diabetes.47.3.450

  4. Betoulle, D

    • Novel polymorphisms in the 5' region of the LEP gene: association with leptin levels and response to low-calorie diet in human obesity. Diabetes March 1998 47:487-489; doi:10.2337/diabetes.47.3.487

  5. Bonner-Weir, S

    • Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes March 1998 47:358-364; doi:10.2337/diabetes.47.3.358

  6. Bossoni, S

    • Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes March 1998 47:423-430; doi:10.2337/diabetes.47.3.423

  7. Bottino, R

    • Transplantation of allogeneic islets of Langerhans in the rat liver: effects of macrophage depletion on graft survival and microenvironment activation. Diabetes March 1998 47:316-323; doi:10.2337/diabetes.47.3.316

  8. Brand, C L

    • Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes March 1998 47:345-351; doi:10.2337/diabetes.47.3.345

  9. Breier, G

    • Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes March 1998 47:401-406; doi:10.2337/diabetes.47.3.401

  10. Brena, C

    • Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes March 1998 47:450-456; doi:10.2337/diabetes.47.3.450

  11. Bretzel, R G

    • Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes March 1998 47:401-406; doi:10.2337/diabetes.47.3.401

  12. Brownlee, M

    • Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes March 1998 47:401-406; doi:10.2337/diabetes.47.3.401

  13. Bruzzi, I

    • Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes March 1998 47:450-456; doi:10.2337/diabetes.47.3.450

  14. Bryan, J

    • Identification and functional analysis of sulfonylurea receptor 1 variants in Japanese patients with NIDDM. Diabetes March 1998 47:476-481; doi:10.2337/diabetes.47.3.476

C

  1. Cambien, F

    • Angiotensin I-converting enzyme gene polymorphism modulates the consequences of in utero growth retardation on plasma insulin in young adults. Diabetes March 1998 47:470-475; doi:10.2337/diabetes.47.3.470

  2. Capeau, J

    • Human peroxisome proliferator-activated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. Diabetes March 1998 47:490-492; doi:10.2337/diabetes.47.3.490

  3. Carr, R D

    • Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes March 1998 47:345-351; doi:10.2337/diabetes.47.3.345

  4. Chrzan, J S

    • Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes March 1998 47:457-463; doi:10.2337/diabetes.47.3.457

  5. Clark, J

    • Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes March 1998 47:358-364; doi:10.2337/diabetes.47.3.358

  6. Cline, G

    • Transgenic mice deficient in the LAR protein-tyrosine phosphatase exhibit profound defects in glucose homeostasis. Diabetes March 1998 47:493-497; doi:10.2337/diabetes.47.3.493

  7. Colas-Linhart, N

    • Novel polymorphisms in the 5' region of the LEP gene: association with leptin levels and response to low-calorie diet in human obesity. Diabetes March 1998 47:487-489; doi:10.2337/diabetes.47.3.487

  8. Collin, D

    • Angiotensin I-converting enzyme gene polymorphism modulates the consequences of in utero growth retardation on plasma insulin in young adults. Diabetes March 1998 47:470-475; doi:10.2337/diabetes.47.3.470

  9. Colosio, V

    • Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes March 1998 47:450-456; doi:10.2337/diabetes.47.3.450

  10. Cooper, M E

    • Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes March 1998 47:414-422; doi:10.2337/diabetes.47.3.414

  11. Cox, A

    • Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes March 1998 47:414-422; doi:10.2337/diabetes.47.3.414

  12. Czernichow, P

    • Angiotensin I-converting enzyme gene polymorphism modulates the consequences of in utero growth retardation on plasma insulin in young adults. Diabetes March 1998 47:470-475; doi:10.2337/diabetes.47.3.470

D

  1. Danska, J S

    • Independent genetic regulation of T-cell and antigen-presenting cell participation in autoimmune islet inflammation. Diabetes March 1998 47:331-338; doi:10.2337/diabetes.47.3.331

  2. Davì, G

    • Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes March 1998 47:423-430; doi:10.2337/diabetes.47.3.423

  3. DeFronzo, R A

    • Insulin-induced hexokinase II expression is reduced in obesity and NIDDM. Diabetes March 1998 47:387-394; doi:10.2337/diabetes.47.3.387

  4. DeGirolami, U

    • Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes March 1998 47:457-463; doi:10.2337/diabetes.47.3.457

  5. Desenzani, P

    • Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes March 1998 47:423-430; doi:10.2337/diabetes.47.3.423

  6. Dhein, S

    • Influence of chronic exposure to high concentrations of D-glucose and long-term beta-blocker treatment on intracellular calcium concentrations of porcine aortic endothelial cells. Diabetes March 1998 47:407-413; doi:10.2337/diabetes.47.3.407

  7. Donaghue, V M

    • Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes March 1998 47:457-463; doi:10.2337/diabetes.47.3.457

E

  1. Efendić, S

    • Mutations in the promoter of adenylyl cyclase (AC)-III gene, overexpression of AC-III mRNA, and enhanced cAMP generation in islets from the spontaneously diabetic GK rat model of type 2 diabetes. Diabetes March 1998 47:498-504; doi:10.2337/diabetes.47.3.498

  2. Engerman, R L

    • Abnormalities of retinal metabolism in diabetes or experimental galactosemia: V. Relationship between protein kinase C and ATPases. Diabetes March 1998 47:464-469; doi:10.2337/diabetes.47.3.464

F

  1. Fagerudd, J A

    • Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes March 1998 47:439-444; doi:10.2337/diabetes.47.3.439

  2. Fajas, L

    • Human peroxisome proliferator-activated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. Diabetes March 1998 47:490-492; doi:10.2337/diabetes.47.3.490

  3. Farid, N

    • Abnormalities of retinal metabolism in diabetes or experimental galactosemia: V. Relationship between protein kinase C and ATPases. Diabetes March 1998 47:464-469; doi:10.2337/diabetes.47.3.464

  4. Fernandez, L A

    • Transplantation of allogeneic islets of Langerhans in the rat liver: effects of macrophage depletion on graft survival and microenvironment activation. Diabetes March 1998 47:316-323; doi:10.2337/diabetes.47.3.316

  5. Fox, C J

    • Independent genetic regulation of T-cell and antigen-presenting cell participation in autoimmune islet inflammation. Diabetes March 1998 47:331-338; doi:10.2337/diabetes.47.3.331

  6. Freeman, R

    • Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes March 1998 47:457-463; doi:10.2337/diabetes.47.3.457

  7. Fuhlendorff, J

    • Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes March 1998 47:345-351; doi:10.2337/diabetes.47.3.345

  8. Fumeron, F

    • Novel polymorphisms in the 5' region of the LEP gene: association with leptin levels and response to low-calorie diet in human obesity. Diabetes March 1998 47:487-489; doi:10.2337/diabetes.47.3.487

G

  1. Gerhardinger, C

    • Müller cell changes in human diabetic retinopathy. Diabetes March 1998 47:445-449; doi:10.2337/diabetes.47.3.445

  2. Gilbert, R E

    • Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes March 1998 47:414-422; doi:10.2337/diabetes.47.3.414

  3. Gilon, P

    • Tolbutamide and diazoxide influence insulin secretion by changing the concentration but not the action of cytoplasmic Ca2+ in beta-cells. Diabetes March 1998 47:365-373; doi:10.2337/diabetes.47.3.365

  4. Giraud, V

    • Novel polymorphisms in the 5' region of the LEP gene: association with leptin levels and response to low-calorie diet in human obesity. Diabetes March 1998 47:487-489; doi:10.2337/diabetes.47.3.487

  5. Giustina, A

    • Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes March 1998 47:423-430; doi:10.2337/diabetes.47.3.423

  6. Glaser, B

    • Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities. Diabetes March 1998 47:307-315; doi:10.2337/diabetes.47.3.307

  7. Goldstein, B J

    • Transgenic mice deficient in the LAR protein-tyrosine phosphatase exhibit profound defects in glucose homeostasis. Diabetes March 1998 47:493-497; doi:10.2337/diabetes.47.3.493

  8. Granner, D

    • Insulin-induced hexokinase II expression is reduced in obesity and NIDDM. Diabetes March 1998 47:387-394; doi:10.2337/diabetes.47.3.387

  9. Grönhagen-Riska, C

    • Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes March 1998 47:439-444; doi:10.2337/diabetes.47.3.439

  10. Groop, P H

    • Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes March 1998 47:439-444; doi:10.2337/diabetes.47.3.439

  11. Guenifi, A

    • Mutations in the promoter of adenylyl cyclase (AC)-III gene, overexpression of AC-III mRNA, and enhanced cAMP generation in islets from the spontaneously diabetic GK rat model of type 2 diabetes. Diabetes March 1998 47:498-504; doi:10.2337/diabetes.47.3.498

  12. Gyapay, G

    • Human peroxisome proliferator-activated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. Diabetes March 1998 47:490-492; doi:10.2337/diabetes.47.3.490

H

  1. Hammes, H P

    • Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes March 1998 47:401-406; doi:10.2337/diabetes.47.3.401

  2. He, B

    • Mutations in the promoter of adenylyl cyclase (AC)-III gene, overexpression of AC-III mRNA, and enhanced cAMP generation in islets from the spontaneously diabetic GK rat model of type 2 diabetes. Diabetes March 1998 47:498-504; doi:10.2337/diabetes.47.3.498

  3. Held, N

    • 13C/31P NMR studies on the mechanism of insulin resistance in obesity. Diabetes March 1998 47:381-386; doi:10.2337/diabetes.47.3.381

  4. Hendler, R

    • 13C/31P NMR studies on the mechanism of insulin resistance in obesity. Diabetes March 1998 47:381-386; doi:10.2337/diabetes.47.3.381

  5. Henquin, J C

    • Tolbutamide and diazoxide influence insulin secretion by changing the concentration but not the action of cytoplasmic Ca2+ in beta-cells. Diabetes March 1998 47:365-373; doi:10.2337/diabetes.47.3.365

  6. Higo, K

    • Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance. Diabetes March 1998 47:395-400; doi:10.2337/diabetes.47.3.395

  7. Hillert, J

    • Mutations in the promoter of adenylyl cyclase (AC)-III gene, overexpression of AC-III mRNA, and enhanced cAMP generation in islets from the spontaneously diabetic GK rat model of type 2 diabetes. Diabetes March 1998 47:498-504; doi:10.2337/diabetes.47.3.498

  8. Höjeberg, B

    • Mutations in the promoter of adenylyl cyclase (AC)-III gene, overexpression of AC-III mRNA, and enhanced cAMP generation in islets from the spontaneously diabetic GK rat model of type 2 diabetes. Diabetes March 1998 47:498-504; doi:10.2337/diabetes.47.3.498

  9. Hosaka, T

    • Identification and functional analysis of sulfonylurea receptor 1 variants in Japanese patients with NIDDM. Diabetes March 1998 47:476-481; doi:10.2337/diabetes.47.3.476

  10. Hulthen, U L

    • Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes March 1998 47:414-422; doi:10.2337/diabetes.47.3.414

I

  1. Ianniello, P

    • Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes March 1998 47:423-430; doi:10.2337/diabetes.47.3.423

  2. Idahl, L A

    • Alpha-ketoisocaproate is not a true substrate for ATP production by pancreatic beta-cell mitochondria. Diabetes March 1998 47:339-344; doi:10.2337/diabetes.47.3.339

  3. Inoue, H

    • Identification and functional analysis of sulfonylurea receptor 1 variants in Japanese patients with NIDDM. Diabetes March 1998 47:476-481; doi:10.2337/diabetes.47.3.476

  4. Inverardi, L

    • Transplantation of allogeneic islets of Langerhans in the rat liver: effects of macrophage depletion on graft survival and microenvironment activation. Diabetes March 1998 47:316-323; doi:10.2337/diabetes.47.3.316

  5. Iozzo, P

    • Insulin-induced hexokinase II expression is reduced in obesity and NIDDM. Diabetes March 1998 47:387-394; doi:10.2337/diabetes.47.3.387

J

  1. Jacobsen, P

    • Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes March 1998 47:439-444; doi:10.2337/diabetes.47.3.439

  2. Jeanclos, E

    • Shortened telomere length in white blood cells of patients with IDDM. Diabetes March 1998 47:482-486; doi:10.2337/diabetes.47.3.482

  3. Jerums, G

    • Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes March 1998 47:414-422; doi:10.2337/diabetes.47.3.414

  4. Jirousek, M R

    • Abnormalities of retinal metabolism in diabetes or experimental galactosemia: V. Relationship between protein kinase C and ATPases. Diabetes March 1998 47:464-469; doi:10.2337/diabetes.47.3.464

K

  1. Kendall, D M

    • Successful islet autotransplantation in humans: functional insulin secretory reserve as an estimate of surviving islet cell mass. Diabetes March 1998 47:324-330; doi:10.2337/diabetes.47.3.324

  2. Kennedy, E D

    • Effects of depletion of mitochondrial DNA in metabolism secretion coupling in INS-1 cells. Diabetes March 1998 47:374-380; doi:10.2337/diabetes.47.3.374

  3. Kern, T S

    • Abnormalities of retinal metabolism in diabetes or experimental galactosemia: V. Relationship between protein kinase C and ATPases. Diabetes March 1998 47:464-469; doi:10.2337/diabetes.47.3.464

  4. Khallouf, E

    • Human peroxisome proliferator-activated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. Diabetes March 1998 47:490-492; doi:10.2337/diabetes.47.3.490

  5. Kimura, M

    • Shortened telomere length in white blood cells of patients with IDDM. Diabetes March 1998 47:482-486; doi:10.2337/diabetes.47.3.482

  6. Kofod, H

    • Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes March 1998 47:345-351; doi:10.2337/diabetes.47.3.345

  7. Komatsu, M

    • Palmitate and myristate selectively mimic the effect of glucose in augmenting insulin release in the absence of extracellular Ca2+. Diabetes March 1998 47:352-357; doi:10.2337/diabetes.47.3.352

  8. Koval, J

    • Insulin-induced hexokinase II expression is reduced in obesity and NIDDM. Diabetes March 1998 47:387-394; doi:10.2337/diabetes.47.3.387

  9. Kowluru, R A

    • Abnormalities of retinal metabolism in diabetes or experimental galactosemia: V. Relationship between protein kinase C and ATPases. Diabetes March 1998 47:464-469; doi:10.2337/diabetes.47.3.464

  10. Krolewski, A

    • Shortened telomere length in white blood cells of patients with IDDM. Diabetes March 1998 47:482-486; doi:10.2337/diabetes.47.3.482

  11. Kubstrup, C

    • Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes March 1998 47:358-364; doi:10.2337/diabetes.47.3.358

  12. Kurachi, Y

    • Identification and functional analysis of sulfonylurea receptor 1 variants in Japanese patients with NIDDM. Diabetes March 1998 47:476-481; doi:10.2337/diabetes.47.3.476

L

  1. Laframboise, M

    • Stimulatory effect of glucose on macrophage lipoprotein lipase expression and production. Diabetes March 1998 47:431-438; doi:10.2337/diabetes.47.3.431

  2. Lambert, A

    • Stimulatory effect of glucose on macrophage lipoprotein lipase expression and production. Diabetes March 1998 47:431-438; doi:10.2337/diabetes.47.3.431

  3. Lascols, O

    • Human peroxisome proliferator-activated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. Diabetes March 1998 47:490-492; doi:10.2337/diabetes.47.3.490

  4. Lee, M K

    • Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance. Diabetes March 1998 47:395-400; doi:10.2337/diabetes.47.3.395

  5. Léger, J

    • Angiotensin I-converting enzyme gene polymorphism modulates the consequences of in utero growth retardation on plasma insulin in young adults. Diabetes March 1998 47:470-475; doi:10.2337/diabetes.47.3.470

  6. Lehmann, R

    • Transplantation of allogeneic islets of Langerhans in the rat liver: effects of macrophage depletion on graft survival and microenvironment activation. Diabetes March 1998 47:316-323; doi:10.2337/diabetes.47.3.316

  7. Lembert, N

    • Alpha-ketoisocaproate is not a true substrate for ATP production by pancreatic beta-cell mitochondria. Diabetes March 1998 47:339-344; doi:10.2337/diabetes.47.3.339

  8. Leone, J P

    • Successful islet autotransplantation in humans: functional insulin secretory reserve as an estimate of surviving islet cell mass. Diabetes March 1998 47:324-330; doi:10.2337/diabetes.47.3.324

  9. Levisetti, M

    • Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes March 1998 47:358-364; doi:10.2337/diabetes.47.3.358

  10. Lévy-Marchal, C

    • Angiotensin I-converting enzyme gene polymorphism modulates the consequences of in utero growth retardation on plasma insulin in young adults. Diabetes March 1998 47:470-475; doi:10.2337/diabetes.47.3.470

  11. Lin, J

    • Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes March 1998 47:401-406; doi:10.2337/diabetes.47.3.401

  12. Li, P M

    • Transgenic mice deficient in the LAR protein-tyrosine phosphatase exhibit profound defects in glucose homeostasis. Diabetes March 1998 47:493-497; doi:10.2337/diabetes.47.3.493

  13. Livingston, J N

    • Transgenic mice deficient in the LAR protein-tyrosine phosphatase exhibit profound defects in glucose homeostasis. Diabetes March 1998 47:493-497; doi:10.2337/diabetes.47.3.493

  14. LoGerfo, F W

    • Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes March 1998 47:457-463; doi:10.2337/diabetes.47.3.457

  15. Lorenzi, M

    • Müller cell changes in human diabetic retinopathy. Diabetes March 1998 47:445-449; doi:10.2337/diabetes.47.3.445

M

  1. MacKay, P

    • Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes March 1998 47:345-351; doi:10.2337/diabetes.47.3.345

  2. Maechler, P

    • Effects of depletion of mitochondrial DNA in metabolism secretion coupling in INS-1 cells. Diabetes March 1998 47:374-380; doi:10.2337/diabetes.47.3.374

  3. Magnuson, M A

    • Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities. Diabetes March 1998 47:307-315; doi:10.2337/diabetes.47.3.307

  4. Magré, J

    • Human peroxisome proliferator-activated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. Diabetes March 1998 47:490-492; doi:10.2337/diabetes.47.3.490

  5. Mallet, C

    • Angiotensin I-converting enzyme gene polymorphism modulates the consequences of in utero growth retardation on plasma insulin in young adults. Diabetes March 1998 47:470-475; doi:10.2337/diabetes.47.3.470

  6. Mammès, O

    • Novel polymorphisms in the 5' region of the LEP gene: association with leptin levels and response to low-calorie diet in human obesity. Diabetes March 1998 47:487-489; doi:10.2337/diabetes.47.3.487

  7. Mandarino, L J

    • Insulin-induced hexokinase II expression is reduced in obesity and NIDDM. Diabetes March 1998 47:387-394; doi:10.2337/diabetes.47.3.387

  8. Mariot, P

    • Tolbutamide and diazoxide influence insulin secretion by changing the concentration but not the action of cytoplasmic Ca2+ in beta-cells. Diabetes March 1998 47:365-373; doi:10.2337/diabetes.47.3.365

  9. Matschinsky, F M

    • Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities. Diabetes March 1998 47:307-315; doi:10.2337/diabetes.47.3.307

  10. Matsutani, A

    • Identification and functional analysis of sulfonylurea receptor 1 variants in Japanese patients with NIDDM. Diabetes March 1998 47:476-481; doi:10.2337/diabetes.47.3.476

  11. Meier, M

    • Human peroxisome proliferator-activated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. Diabetes March 1998 47:490-492; doi:10.2337/diabetes.47.3.490

  12. Milani, M

    • Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes March 1998 47:423-430; doi:10.2337/diabetes.47.3.423

  13. Miles, P D

    • Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance. Diabetes March 1998 47:395-400; doi:10.2337/diabetes.47.3.395

  14. Mizutani, M

    • Müller cell changes in human diabetic retinopathy. Diabetes March 1998 47:445-449; doi:10.2337/diabetes.47.3.445

  15. Mustafa, M

    • Mutations in the promoter of adenylyl cyclase (AC)-III gene, overexpression of AC-III mRNA, and enhanced cAMP generation in islets from the spontaneously diabetic GK rat model of type 2 diabetes. Diabetes March 1998 47:498-504; doi:10.2337/diabetes.47.3.498

N

  1. Nenquin, M

    • Tolbutamide and diazoxide influence insulin secretion by changing the concentration but not the action of cytoplasmic Ca2+ in beta-cells. Diabetes March 1998 47:365-373; doi:10.2337/diabetes.47.3.365

  2. Nielsen, F S

    • Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes March 1998 47:439-444; doi:10.2337/diabetes.47.3.439

O

  1. Ohta, Y

    • Identification and functional analysis of sulfonylurea receptor 1 variants in Japanese patients with NIDDM. Diabetes March 1998 47:476-481; doi:10.2337/diabetes.47.3.476

  2. Oka, Y

    • Identification and functional analysis of sulfonylurea receptor 1 variants in Japanese patients with NIDDM. Diabetes March 1998 47:476-481; doi:10.2337/diabetes.47.3.476

  3. Olefsky, J M

    • Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance. Diabetes March 1998 47:395-400; doi:10.2337/diabetes.47.3.395

  4. Oliver, R

    • Transplantation of allogeneic islets of Langerhans in the rat liver: effects of macrophage depletion on graft survival and microenvironment activation. Diabetes March 1998 47:316-323; doi:10.2337/diabetes.47.3.316

P

  1. Parving, H H

    • Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes March 1998 47:439-444; doi:10.2337/diabetes.47.3.439

  2. Pendergrass, M

    • Insulin-induced hexokinase II expression is reduced in obesity and NIDDM. Diabetes March 1998 47:387-394; doi:10.2337/diabetes.47.3.387

  3. Perini, P

    • Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes March 1998 47:423-430; doi:10.2337/diabetes.47.3.423

  4. Permutt, M A

    • Identification and functional analysis of sulfonylurea receptor 1 variants in Japanese patients with NIDDM. Diabetes March 1998 47:476-481; doi:10.2337/diabetes.47.3.476

  5. Perseghin, G

    • 13C/31P NMR studies on the mechanism of insulin resistance in obesity. Diabetes March 1998 47:381-386; doi:10.2337/diabetes.47.3.381

  6. Petersen, K F

    • 13C/31P NMR studies on the mechanism of insulin resistance in obesity. Diabetes March 1998 47:381-386; doi:10.2337/diabetes.47.3.381

  7. Petiet, A

    • Novel polymorphisms in the 5' region of the LEP gene: association with leptin levels and response to low-calorie diet in human obesity. Diabetes March 1998 47:487-489; doi:10.2337/diabetes.47.3.487

  8. Pettersson-Fernholm, K J

    • Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes March 1998 47:439-444; doi:10.2337/diabetes.47.3.439

  9. Pick, A

    • Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes March 1998 47:358-364; doi:10.2337/diabetes.47.3.358

  10. Pipek, R

    • Insulin-induced hexokinase II expression is reduced in obesity and NIDDM. Diabetes March 1998 47:387-394; doi:10.2337/diabetes.47.3.387

  11. Polonsky, K S

    • Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes March 1998 47:358-364; doi:10.2337/diabetes.47.3.358

  12. Price, T

    • 13C/31P NMR studies on the mechanism of insulin resistance in obesity. Diabetes March 1998 47:381-386; doi:10.2337/diabetes.47.3.381

  13. Primavera, J

    • Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes March 1998 47:457-463; doi:10.2337/diabetes.47.3.457

  14. Printz, R

    • Insulin-induced hexokinase II expression is reduced in obesity and NIDDM. Diabetes March 1998 47:387-394; doi:10.2337/diabetes.47.3.387

  15. Pugh, W

    • Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes March 1998 47:358-364; doi:10.2337/diabetes.47.3.358

R

  1. Rafaat, K

    • Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance. Diabetes March 1998 47:395-400; doi:10.2337/diabetes.47.3.395

  2. Remuzzi, G

    • Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes March 1998 47:450-456; doi:10.2337/diabetes.47.3.450

  3. Renier, G

    • Stimulatory effect of glucose on macrophage lipoprotein lipase expression and production. Diabetes March 1998 47:431-438; doi:10.2337/diabetes.47.3.431

  4. Ren, J M

    • Transgenic mice deficient in the LAR protein-tyrosine phosphatase exhibit profound defects in glucose homeostasis. Diabetes March 1998 47:493-497; doi:10.2337/diabetes.47.3.493

  5. Repunte, V P

    • Identification and functional analysis of sulfonylurea receptor 1 variants in Japanese patients with NIDDM. Diabetes March 1998 47:476-481; doi:10.2337/diabetes.47.3.476

  6. Ricordi, C

    • Transplantation of allogeneic islets of Langerhans in the rat liver: effects of macrophage depletion on graft survival and microenvironment activation. Diabetes March 1998 47:316-323; doi:10.2337/diabetes.47.3.316

  7. Robertson, R P

    • Successful islet autotransplantation in humans: functional insulin secretory reserve as an estimate of surviving islet cell mass. Diabetes March 1998 47:324-330; doi:10.2337/diabetes.47.3.324

  8. Rolin, B

    • Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes March 1998 47:345-351; doi:10.2337/diabetes.47.3.345

  9. Romanelli, G

    • Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes March 1998 47:423-430; doi:10.2337/diabetes.47.3.423

  10. Romeo, O M

    • Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance. Diabetes March 1998 47:395-400; doi:10.2337/diabetes.47.3.395

  11. Rorsman, P

    • Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes March 1998 47:345-351; doi:10.2337/diabetes.47.3.345

  12. Rothman, D L

    • 13C/31P NMR studies on the mechanism of insulin resistance in obesity. Diabetes March 1998 47:381-386; doi:10.2337/diabetes.47.3.381

S

  1. Salameh, A

    • Influence of chronic exposure to high concentrations of D-glucose and long-term beta-blocker treatment on intracellular calcium concentrations of porcine aortic endothelial cells. Diabetes March 1998 47:407-413; doi:10.2337/diabetes.47.3.407

  2. Sartippour, M R

    • Stimulatory effect of glucose on macrophage lipoprotein lipase expression and production. Diabetes March 1998 47:431-438; doi:10.2337/diabetes.47.3.431

  3. Sharp, G W

    • Palmitate and myristate selectively mimic the effect of glucose in augmenting insulin release in the absence of extracellular Ca2+. Diabetes March 1998 47:352-357; doi:10.2337/diabetes.47.3.352

  4. Shulman, G I

    • 13C/31P NMR studies on the mechanism of insulin resistance in obesity. Diabetes March 1998 47:381-386; doi:10.2337/diabetes.47.3.381
    • Transgenic mice deficient in the LAR protein-tyrosine phosphatase exhibit profound defects in glucose homeostasis. Diabetes March 1998 47:493-497; doi:10.2337/diabetes.47.3.493

  5. Shymko, R

    • Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes March 1998 47:345-351; doi:10.2337/diabetes.47.3.345

  6. Skurnick, J

    • Shortened telomere length in white blood cells of patients with IDDM. Diabetes March 1998 47:482-486; doi:10.2337/diabetes.47.3.482

  7. Smets, Y F

    • Successful islet autotransplantation in humans: functional insulin secretory reserve as an estimate of surviving islet cell mass. Diabetes March 1998 47:324-330; doi:10.2337/diabetes.47.3.324

  8. Stenman, S

    • Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes March 1998 47:439-444; doi:10.2337/diabetes.47.3.439

  9. St-Jacques, P

    • Stimulatory effect of glucose on macrophage lipoprotein lipase expression and production. Diabetes March 1998 47:431-438; doi:10.2337/diabetes.47.3.431

  10. Stramm, L

    • Abnormalities of retinal metabolism in diabetes or experimental galactosemia: V. Relationship between protein kinase C and ATPases. Diabetes March 1998 47:464-469; doi:10.2337/diabetes.47.3.464

  11. Sutherland, D E

    • Successful islet autotransplantation in humans: functional insulin secretory reserve as an estimate of surviving islet cell mass. Diabetes March 1998 47:324-330; doi:10.2337/diabetes.47.3.324

  12. Sweet, L J

    • Transgenic mice deficient in the LAR protein-tyrosine phosphatase exhibit profound defects in glucose homeostasis. Diabetes March 1998 47:493-497; doi:10.2337/diabetes.47.3.493

T

  1. Tanizawa, Y

    • Identification and functional analysis of sulfonylurea receptor 1 variants in Japanese patients with NIDDM. Diabetes March 1998 47:476-481; doi:10.2337/diabetes.47.3.476

  2. Tarnow, L

    • Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes March 1998 47:439-444; doi:10.2337/diabetes.47.3.439

  3. Teuscher, A U

    • Successful islet autotransplantation in humans: functional insulin secretory reserve as an estimate of surviving islet cell mass. Diabetes March 1998 47:324-330; doi:10.2337/diabetes.47.3.324

  4. Tsan, M F

    • Transplantation of allogeneic islets of Langerhans in the rat liver: effects of macrophage depletion on graft survival and microenvironment activation. Diabetes March 1998 47:316-323; doi:10.2337/diabetes.47.3.316

  5. Tuzet, S

    • Novel polymorphisms in the 5' region of the LEP gene: association with leptin levels and response to low-calorie diet in human obesity. Diabetes March 1998 47:487-489; doi:10.2337/diabetes.47.3.487

U

  1. Ueda, K

    • Identification and functional analysis of sulfonylurea receptor 1 variants in Japanese patients with NIDDM. Diabetes March 1998 47:476-481; doi:10.2337/diabetes.47.3.476

V

  1. Veves, A

    • Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes March 1998 47:457-463; doi:10.2337/diabetes.47.3.457

  2. Vigouroux, C

    • Human peroxisome proliferator-activated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. Diabetes March 1998 47:490-492; doi:10.2337/diabetes.47.3.490

  3. Vogt, C

    • Insulin-induced hexokinase II expression is reduced in obesity and NIDDM. Diabetes March 1998 47:387-394; doi:10.2337/diabetes.47.3.387

W

  1. Warram, J H

    • Shortened telomere length in white blood cells of patients with IDDM. Diabetes March 1998 47:482-486; doi:10.2337/diabetes.47.3.482

  2. Weissenbach, J

    • Human peroxisome proliferator-activated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. Diabetes March 1998 47:490-492; doi:10.2337/diabetes.47.3.490

  3. Wollheim, C B

    • Effects of depletion of mitochondrial DNA in metabolism secretion coupling in INS-1 cells. Diabetes March 1998 47:374-380; doi:10.2337/diabetes.47.3.374

  4. Wu, L L

    • Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes March 1998 47:414-422; doi:10.2337/diabetes.47.3.414

Y

  1. Yamada, M

    • Identification and functional analysis of sulfonylurea receptor 1 variants in Japanese patients with NIDDM. Diabetes March 1998 47:476-481; doi:10.2337/diabetes.47.3.476

  2. Yang, B

    • Mutations in the promoter of adenylyl cyclase (AC)-III gene, overexpression of AC-III mRNA, and enhanced cAMP generation in islets from the spontaneously diabetic GK rat model of type 2 diabetes. Diabetes March 1998 47:498-504; doi:10.2337/diabetes.47.3.498

  3. Yki-Jarvinen, H

    • Insulin-induced hexokinase II expression is reduced in obesity and NIDDM. Diabetes March 1998 47:387-394; doi:10.2337/diabetes.47.3.387

Z

  1. Zacharoulis, D

    • Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes March 1998 47:457-463; doi:10.2337/diabetes.47.3.457

  2. Zhang, W R

    • Transgenic mice deficient in the LAR protein-tyrosine phosphatase exhibit profound defects in glucose homeostasis. Diabetes March 1998 47:493-497; doi:10.2337/diabetes.47.3.493

Current Issue

  1. February 2012, 61 (2)
  1. Current Issue
  1. Alert me to new issues of Diabetes
Advertisement